UPDATE: RBC Maintains Sarepta At Outperform, Raises Tgt To $220 As Firm Sees Co. 'as the clear leader in this space and are increasing our out-year DMD share/penetration estimates' 'Based on our analysis of PFE's initial DMD gene therapy results'
Benzinga_Newsdesk